Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529230 · ClinicalTrials.gov registry record
Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 46
- Enrollment target
NCT00529230: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT00529230 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00529230 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 46 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To determine the prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes. Secondary Objective: 1\. To determine the degree of sexual dysfunction, fatigue, and depression prevalent in male patients on chronic opioid therapy for cancer-related pain syndromes.
Interventions
- BEHAVIORAL Questionnaire
- OTHER Blood draws to assess gonadal function
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2001-12-11 |
| Est. Completion | 2004-02-19 |
Why NCT00529230 stopped before completion
NCT00529230 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire is the first listed.
NCT00529230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00529230 about?
NCT00529230 is a clinical study titled "Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes". Primary Objective: 1\. To determine the prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes. Secondary Objective: 1\. To determine the degree of sexual dysfunction, fatigue, and depression prevalent in male patients on chronic opioid t...
What is the current status of trial NCT00529230?
This trial is currently terminated. The enrollment target is 46 participants. The study started on 2001-12-11. Estimated completion is 2004-02-19.
What interventions are being tested in trial NCT00529230?
The interventions under investigation include: Questionnaire (BEHAVIORAL), Blood draws to assess gonadal function (OTHER).
Who is sponsoring clinical trial NCT00529230?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI